中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2014年
28期
81-82
,共2页
黄芪注射液%丹参注射液%脑蛋白水解物%脑梗塞后抑郁症
黃芪註射液%丹參註射液%腦蛋白水解物%腦梗塞後抑鬱癥
황기주사액%단삼주사액%뇌단백수해물%뇌경새후억욱증
Huangqi injection%Danshen injection%Cerebroprotein Hydrolysate%Post-cerebral infarction depression
目的：探讨黄芪注射液对比脑蛋白水解物治疗脑梗塞后抑郁症的疗效观察。方法：回顾性分析2012年5月-2013年8月期间因脑梗塞后抑郁症入院的患者64例，按计划分为两组，每组32例，分别予以黄芪注射液（观察组）和脑蛋白水解物（对照组），比较两组患者治疗后临床效果、HAMD 评分、SDS 评分以及不良反应发生情况。结果：观察组显效率78.1%明显高于对照组43.8%，治疗后HAMD评分（16.1±4.3）明显低于对照组（25.2±4.0），SDS评分（51.7±3.6）明显低于对照组（59.9±4.1），总不良反应15.7%明显低于对照组31.3%。结论：黄芪注射液对于治疗脑梗塞后抑郁症临床疗效明显，HAMD评分和SDS评分下降显著，不良反应发生率低，适合临床广泛应用。
目的：探討黃芪註射液對比腦蛋白水解物治療腦梗塞後抑鬱癥的療效觀察。方法：迴顧性分析2012年5月-2013年8月期間因腦梗塞後抑鬱癥入院的患者64例，按計劃分為兩組，每組32例，分彆予以黃芪註射液（觀察組）和腦蛋白水解物（對照組），比較兩組患者治療後臨床效果、HAMD 評分、SDS 評分以及不良反應髮生情況。結果：觀察組顯效率78.1%明顯高于對照組43.8%，治療後HAMD評分（16.1±4.3）明顯低于對照組（25.2±4.0），SDS評分（51.7±3.6）明顯低于對照組（59.9±4.1），總不良反應15.7%明顯低于對照組31.3%。結論：黃芪註射液對于治療腦梗塞後抑鬱癥臨床療效明顯，HAMD評分和SDS評分下降顯著，不良反應髮生率低，適閤臨床廣汎應用。
목적：탐토황기주사액대비뇌단백수해물치료뇌경새후억욱증적료효관찰。방법：회고성분석2012년5월-2013년8월기간인뇌경새후억욱증입원적환자64례，안계화분위량조，매조32례，분별여이황기주사액（관찰조）화뇌단백수해물（대조조），비교량조환자치료후림상효과、HAMD 평분、SDS 평분이급불량반응발생정황。결과：관찰조현효솔78.1%명현고우대조조43.8%，치료후HAMD평분（16.1±4.3）명현저우대조조（25.2±4.0），SDS평분（51.7±3.6）명현저우대조조（59.9±4.1），총불량반응15.7%명현저우대조조31.3%。결론：황기주사액대우치료뇌경새후억욱증림상료효명현，HAMD평분화SDS평분하강현저，불량반응발생솔저，괄합림상엄범응용。
Objective:To compare the curative effect between Huangqi injection and cerebroprotein hydrolysate on post-cerebral infarction depression. Methods:Retrospectively analyzing the clinical data of 64 patients with post-cerebral infarction depression from May 2012 to Aug. 2013 in our hospital. According to the plan, we divided them into 2 groups, with 32 cases in each group. One group was treated with Huangqi injection (observation group) , and another was given cerebroprotein hydrolysate (control group). Then we analyzed and compared the clinical data of the two groups, including HAMD score, SDS score and adverse reaction. Results:The effective rate of the observation group (78.1%) is significantly higher than that in control group (43.8%) after treatment;HAMD score of the observation group (16.1±4.3) is lower than that in the control group (25.2±4.0);SDS score of the observation group (51.7±3.6) is lower than that in the control group (59.9±4.1);the total adverse reaction rate of the observation group (15.7%) is significantly lower than the control group (31.3%). Conclusion: Huangqi injection is more suitable for clinical application, for its good clinical curative effect, low HAMD score, SDS score and adverse reaction rate.
